MiniMed Launches First MiniMed Flex System in the U.S.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2026
0mins
MiniMed announced its first commercial launch of the MiniMed Flex system in the U.S.- its first app-controlled pump and the company's smallest insulin pump yet. The system launches with Simplera Sync sensor, a disposable, all-in-one sensor with easy two-step insertion. The launch with the Instinct sensor, made by Abbott, will follow later this summer. For years, people who use insulin pumps have had to think about where and how they wear their device each day. While diabetes technology has advanced, many still had to choose between clinical performance and a pump that works with their lifestyle. Few products have offered both. The MiniMed Flex system is powered by MiniMed's most advanced SmartGuard algorithm - the only system with Meal Detection(TM) technology that detects rapid rises in sensor glucose and delivers a correction dose for occasional missed meal boluses or underestimated carb counts. The MiniMed Flex system is FDA cleared for people with type 1 diabetes ages 7 years and older, as well as adults ages 18 years and older with insulin-requiring type 2 diabetes. Reimbursement support and access programs are available through MiniMed's customer support team.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MMED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MMED
Wall Street analysts forecast MMED stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 14.240
Low
Averages
High
Current: 14.240
Low
Averages
High
About MMED
MiniMed Group, Inc. is a medical technology company, which develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Its fully integrated system addresses pain points for people with diabetes (PWD): health outcomes and complexity of diabetes management. The MiniMed 780G is its flagship AID system. The MiniMed 780G system uses its SmartGuard dosing algorithm technology, which automatically delivers basal insulin and auto-correction doses every five minutes based on sensor glucose readings. The MiniMed 780G consists of the MiniMed 780G insulin pump, the Simplera Sync CGM sensor, and the instinct sensor. Its platform of clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and a Smart Multiple Daily Injection (MDI) System. Its pipeline products are the MiniMed Flex, screenless insulin pump, next-generation Vivera dosing algorithm, and MiniMed Fit patch pump with extended wear.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MiniMed Expands Board with New Members
- Board Expansion: MiniMed announces the addition of David Endicott and Linnea Burman to its Board of Directors, increasing the board size from nine to eleven members, aimed at enhancing leadership and strategic execution as the company operates independently.
- Leadership Experience: Endicott, as CEO of Alcon, brings global healthcare leadership experience, particularly in public market separation and operations in large regulated sectors, which is expected to provide significant support for MiniMed's growth and technological advancements.
- Strategic Role Allocation: Endicott will serve on the Board's Compensation and Talent Committee, while Burman, as Senior Vice President at Medtronic, strengthens MiniMed's leadership position in diabetes technology, enhancing operational depth and strategic insight.
- Technological and Market Impact: MiniMed is committed to improving the quality of life for diabetes patients through advanced insulin delivery systems and CGM technology, with new board members expected to drive market expansion and innovation across over 80 countries.
See More
MiniMed Expands Board with New Members
- Board Expansion: MiniMed announces the addition of David Endicott and Linnea Burman to its Board of Directors, increasing the board size from nine to eleven members, aimed at enhancing leadership and strategic execution in its independent operations.
- Leadership Experience: Endicott, as CEO of Alcon, brings global healthcare leadership experience, particularly in public market separation and operations in large regulated sectors, which is crucial for MiniMed's future growth.
- Technology and Market Opportunities: Endicott stated that MiniMed has a long history in diabetes care and a clear opportunity to simplify care for more people, which will drive advancements in the company's technology and expand its global impact.
- Shareholder Support: Medtronic plc, as the majority shareholder of MiniMed, continues to support the company's independent development and has designated Burman to the board, further strengthening the board's operational and strategic leadership capabilities.
See More
MiniMed Launches First App-Controlled Insulin Pump in the U.S.
- Product Innovation: MiniMed has launched its first MiniMed Flex™ system in the U.S., which is the company's smallest insulin pump to date, representing a significant technological advancement in diabetes management that is expected to enhance patient experience and adherence.
- Smart Control: The system features the Simplera Sync™ sensor, designed for easy two-step insertion and disposable use, aiming to simplify user operations and thereby improve daily management efficiency for diabetes patients.
- Market Potential: The introduction of the MiniMed Flex™ system addresses the U.S. demand for portable and smart insulin pumps, likely attracting more insulin-dependent type 1 and type 2 diabetes patients and further expanding the company's market share.
- Future Plans: MiniMed plans to launch a compatible product with the Instinct sensor made by Abbott later this summer, which will further enhance the competitiveness of its product line and drive ongoing innovation in diabetes management.
See More
MiniMed Launches First Smart Insulin Pump in the U.S.
- Product Launch: MiniMed has launched its first smart insulin pump, the MiniMed Flex™, in the U.S., which is the company's smallest model yet, capable of holding 300 units of insulin, aimed at providing a more flexible lifestyle for type 1 and insulin-requiring type 2 diabetes patients.
- Technological Innovation: The MiniMed Flex™ system features the Simplera Sync™ sensor with an easy two-step insertion process, while its SmartGuard™ algorithm can automatically adjust insulin delivery every five minutes, helping users maintain 80% Time in Range (TIR).
- Enhanced User Experience: The system is designed to simplify diabetes management in daily life, reducing the number of injections required compared to traditional insulin therapy, allowing users to benefit from up to seven days of wear, significantly improving quality of life.
- Market Potential: The MiniMed Flex™ system is FDA cleared for individuals aged 7 and older with type 1 diabetes and adults aged 18 and older with insulin-requiring type 2 diabetes, which is expected to drive further growth for the company in the diabetes management market.
See More
Investment Opportunities in Blue-Chip Stocks Amid AI Boom
- REIT Investment Trust: Realty Income (O), a leading real estate investment trust with a market cap of $57 billion, focuses on retail properties and pays a monthly dividend of 5.28%, having increased its payout for over 30 consecutive years, showcasing resilience and appeal amid economic fluctuations.
- Stability of Fast Food Giant: McDonald's (MCD), with over 45,000 locations worldwide, boasts 49 years of annual dividend growth and is on the verge of becoming a Dividend King, with its brand value allowing it to maintain steady revenue during economic downturns, making it attractive for long-term investors.
- Durable Demand for Home Products: Clorox (CLX) holds a significant position in the home products market with its trusted brands, and despite facing high costs and cybersecurity issues, its 48-year dividend growth streak positions it as a potential Dividend King, with the recent acquisition of Purell expected to enhance profitability.
- Long-Term Growth in Healthcare: Medtronic (MDT), a leading global healthcare company with a market cap of $105 billion, is poised for its 50th consecutive annual dividend increase next year, and its expansion into robotic-assisted surgery, along with a projected 6%-7% annual earnings growth, makes it highly attractive in the current market.
See More
Investment Opportunities in Blue-Chip Stocks Amid AI Craze
- Real Estate Investment Trust: Realty Income (NYSE: O) focuses on retail properties and has increased its dividend for over 30 consecutive years, currently yielding 5.3%, demonstrating stability during economic fluctuations and attracting long-term investors.
- Fast Food Giant: McDonald's (NYSE: MCD) operates over 45,000 locations globally and continues to pay and increase dividends, achieving 49 consecutive years of hikes, positioning it to become a Dividend King and showcasing resilience during economic downturns.
- Household Products Market: Clorox (NYSE: CLX) boasts a 48-year dividend growth streak, and despite facing high costs and cybersecurity issues, it maintains a 5.2% dividend yield, reflecting strong demand for its trusted brands even in economic volatility.
- Healthcare Sector Outlook: Medtronic (NYSE: MDT) is poised for its 50th consecutive dividend increase with a current yield of 3.5%, and its expansion into robotic-assisted surgery and new product launches indicate significant growth potential, making it an attractive option for investors.
See More
MiniMed Expands Board with New Members
- Board Expansion: MiniMed announces the addition of David Endicott and Linnea Burman to its Board of Directors, increasing the board size from nine to eleven members, aimed at enhancing leadership and strategic execution as the company operates independently.
- Leadership Experience: Endicott, as CEO of Alcon, brings global healthcare leadership experience, particularly in public market separation and operations in large regulated sectors, which is expected to provide significant support for MiniMed's growth and technological advancements.
- Strategic Role Allocation: Endicott will serve on the Board's Compensation and Talent Committee, while Burman, as Senior Vice President at Medtronic, strengthens MiniMed's leadership position in diabetes technology, enhancing operational depth and strategic insight.
- Technological and Market Impact: MiniMed is committed to improving the quality of life for diabetes patients through advanced insulin delivery systems and CGM technology, with new board members expected to drive market expansion and innovation across over 80 countries.
See More
MiniMed Expands Board with New Members
- Board Expansion: MiniMed announces the addition of David Endicott and Linnea Burman to its Board of Directors, increasing the board size from nine to eleven members, aimed at enhancing leadership and strategic execution in its independent operations.
- Leadership Experience: Endicott, as CEO of Alcon, brings global healthcare leadership experience, particularly in public market separation and operations in large regulated sectors, which is crucial for MiniMed's future growth.
- Technology and Market Opportunities: Endicott stated that MiniMed has a long history in diabetes care and a clear opportunity to simplify care for more people, which will drive advancements in the company's technology and expand its global impact.
- Shareholder Support: Medtronic plc, as the majority shareholder of MiniMed, continues to support the company's independent development and has designated Burman to the board, further strengthening the board's operational and strategic leadership capabilities.
See More
MiniMed Launches First App-Controlled Insulin Pump in the U.S.
- Product Innovation: MiniMed has launched its first MiniMed Flex™ system in the U.S., which is the company's smallest insulin pump to date, representing a significant technological advancement in diabetes management that is expected to enhance patient experience and adherence.
- Smart Control: The system features the Simplera Sync™ sensor, designed for easy two-step insertion and disposable use, aiming to simplify user operations and thereby improve daily management efficiency for diabetes patients.
- Market Potential: The introduction of the MiniMed Flex™ system addresses the U.S. demand for portable and smart insulin pumps, likely attracting more insulin-dependent type 1 and type 2 diabetes patients and further expanding the company's market share.
- Future Plans: MiniMed plans to launch a compatible product with the Instinct sensor made by Abbott later this summer, which will further enhance the competitiveness of its product line and drive ongoing innovation in diabetes management.
See More
MiniMed Launches First Smart Insulin Pump in the U.S.
- Product Launch: MiniMed has launched its first smart insulin pump, the MiniMed Flex™, in the U.S., which is the company's smallest model yet, capable of holding 300 units of insulin, aimed at providing a more flexible lifestyle for type 1 and insulin-requiring type 2 diabetes patients.
- Technological Innovation: The MiniMed Flex™ system features the Simplera Sync™ sensor with an easy two-step insertion process, while its SmartGuard™ algorithm can automatically adjust insulin delivery every five minutes, helping users maintain 80% Time in Range (TIR).
- Enhanced User Experience: The system is designed to simplify diabetes management in daily life, reducing the number of injections required compared to traditional insulin therapy, allowing users to benefit from up to seven days of wear, significantly improving quality of life.
- Market Potential: The MiniMed Flex™ system is FDA cleared for individuals aged 7 and older with type 1 diabetes and adults aged 18 and older with insulin-requiring type 2 diabetes, which is expected to drive further growth for the company in the diabetes management market.
See More
Investment Opportunities in Blue-Chip Stocks Amid AI Boom
- REIT Investment Trust: Realty Income (O), a leading real estate investment trust with a market cap of $57 billion, focuses on retail properties and pays a monthly dividend of 5.28%, having increased its payout for over 30 consecutive years, showcasing resilience and appeal amid economic fluctuations.
- Stability of Fast Food Giant: McDonald's (MCD), with over 45,000 locations worldwide, boasts 49 years of annual dividend growth and is on the verge of becoming a Dividend King, with its brand value allowing it to maintain steady revenue during economic downturns, making it attractive for long-term investors.
- Durable Demand for Home Products: Clorox (CLX) holds a significant position in the home products market with its trusted brands, and despite facing high costs and cybersecurity issues, its 48-year dividend growth streak positions it as a potential Dividend King, with the recent acquisition of Purell expected to enhance profitability.
- Long-Term Growth in Healthcare: Medtronic (MDT), a leading global healthcare company with a market cap of $105 billion, is poised for its 50th consecutive annual dividend increase next year, and its expansion into robotic-assisted surgery, along with a projected 6%-7% annual earnings growth, makes it highly attractive in the current market.
See More
Investment Opportunities in Blue-Chip Stocks Amid AI Craze
- Real Estate Investment Trust: Realty Income (NYSE: O) focuses on retail properties and has increased its dividend for over 30 consecutive years, currently yielding 5.3%, demonstrating stability during economic fluctuations and attracting long-term investors.
- Fast Food Giant: McDonald's (NYSE: MCD) operates over 45,000 locations globally and continues to pay and increase dividends, achieving 49 consecutive years of hikes, positioning it to become a Dividend King and showcasing resilience during economic downturns.
- Household Products Market: Clorox (NYSE: CLX) boasts a 48-year dividend growth streak, and despite facing high costs and cybersecurity issues, it maintains a 5.2% dividend yield, reflecting strong demand for its trusted brands even in economic volatility.
- Healthcare Sector Outlook: Medtronic (NYSE: MDT) is poised for its 50th consecutive dividend increase with a current yield of 3.5%, and its expansion into robotic-assisted surgery and new product launches indicate significant growth potential, making it an attractive option for investors.
See More
